1. Overview of USFDA Inspection Trends in 2026

The United States Food and Drug Administration (USFDA or FDA) regulates pharmaceutical manufacturing to ensure that medicines are safe, effective, and consistently manufactured in accordance with applicable requirements.

The agency’s inspection approach is risk-based. Inspection priorities can be influenced by a facility’s compliance history, product risk, manufacturing complexity, quality signals, recalls, and other relevant information.

In 2026, several important developments are shaping the inspection environment:

• Increased use of unannounced inspections at selected foreign manufacturing facilities.
• Continued emphasis on risk-based inspection scheduling and resource allocation.
• Greater use of records requests and remote assessment tools where appropriate.
• Detailed scrutiny of investigations, CAPA, laboratory controls, and data integrity.
• Continued focus on contamination prevention, equipment maintenance, and process control.
• Stronger attention to supply chain reliability and the maturity of pharmaceutical quality systems.

In its 2026 communication on modernizing inspection operations, the FDA described efforts to improve inspection coverage through risk-informed planning, coordination, and the use of alternative oversight tools. The agency also reported increasing the proportion of unannounced foreign inspections.

These developments should not be interpreted as a new universal checklist or a guarantee that every inspection will cover the same topics. Inspection scope depends on the facility, products, operations, application status, and relevant risk factors.

Reference: FDA: Investing in FDA’s Inspectional Enterprise.

2. Increased Focus on Unannounced Foreign Inspections

One of the most significant recent developments for pharmaceutical manufacturers outside the United States is the FDA’s increased use of unannounced inspections at selected foreign facilities.

In its 2026 update, the FDA reported the following figures for inspections conducted by its foreign offices:

Source: FDA communication on inspectional enterprise modernization. FY 2026 figures are year-to-date figures reported in the communication, not full-year totals.

These figures demonstrate a substantial change in inspection practices. They do not mean that every foreign facility will receive an unannounced inspection or that every inspection will follow the same approach.

What does this mean for Indian pharmaceutical companies?

Manufacturers supplying products to the US market should maintain continuous inspection readiness rather than depending on a short preparation period after receiving an inspection notification.

Important actions include:

• Maintain GMP compliance during routine production, not only before audits.
• Ensure approved procedures are followed on every shift.
• Keep manufacturing and laboratory records complete, accurate, and readily retrievable.
• Ensure responsible personnel can explain their processes and associated controls.
• Keep deviation, CAPA, change control, and validation records current.
• Ensure audit trails, electronic records, and supporting raw data are accessible.
• Verify that contract manufacturers and critical suppliers are appropriately qualified and monitored.

Practical takeaway: Inspection readiness must be a daily operating discipline supported by effective systems, trained personnel, and management oversight.

3. Risk-Based Inspection Planning

The FDA uses a risk-based approach to determine which facilities require inspection and what level of regulatory attention may be appropriate.

Factors that can influence inspection priority include:

• Previous inspection history and compliance status.
• Product type, dosage form, and patient risk.
• Known quality problems, recalls, and other relevant signals.
• Manufacturing complexity and the facility’s demonstrated capabilities.
• Relevant information from other trusted regulatory authorities.
• The reliability of information provided in regulatory applications.

For example, a facility manufacturing sterile products with significant contamination-control risks may require a different level of inspectional attention from a facility manufacturing conventional oral solid dosage forms with a strong compliance history.

How should QA teams prepare?

QA should periodically evaluate facility risks using a documented and scientifically justified approach. The assessment should consider deviations, repeat observations, complaints, OOS/OOT results, CAPA effectiveness, process performance, supplier issues, and overdue quality actions.

Trending should be used to identify systemic weaknesses before they develop into significant compliance problems.

Reference: FDA’s Risk-Based Approach to Inspections.

4. Data Integrity and Electronic Records

Data integrity remains an important area of pharmaceutical GMP compliance. Investigators may examine whether manufacturing, laboratory, and quality records accurately represent the activities performed and results obtained.

Digital transformation has increased the importance of appropriate access controls, audit trails, electronic signatures, backup procedures, system validation, and data governance.

Important areas of review

ALCOA+ principles

Pharmaceutical data should follow the principles of attributable, legible, contemporaneous, original, and accurate data. The extended ALCOA+ framework also emphasizes completeness, consistency, endurance, and availability.

Companies should ensure that original data and relevant metadata are preserved, that changes are traceable, and that access permissions reflect actual job responsibilities.

Shared user accounts, undocumented data manipulation, inappropriate audit-trail practices, and incomplete raw-data retention can undermine confidence in the reliability of GMP records.

For further reading, see the FDA guidance on Data Integrity and Compliance With Drug CGMP.

5. Deviations, Investigations, and Root Cause Analysis

A recurring quality-system weakness is the failure to investigate an event thoroughly and determine its actual or most probable root cause.

Merely documenting an incident, assigning retraining, or repeating a test does not necessarily establish why the failure occurred or demonstrate that the risk has been adequately controlled.

What should an effective investigation contain?

1. Clear event description: Document what happened, when it happened, where it occurred, and how it was detected.
2. Immediate containment: Assess affected batches, equipment, records, materials, and products.
3. Scope assessment: Identify other batches, products, processes, shifts, and time periods that could be affected.
4. Evidence collection: Review original records, audit trails, process parameters, equipment history, and relevant interviews.
5. Root cause analysis: Apply suitable tools such as fishbone analysis, 5 Whys, fault-tree analysis, or other scientifically appropriate methods.
6. Impact assessment: Evaluate product quality, patient safety, data reliability, and regulatory implications.
7. CAPA: Define proportionate corrective and preventive actions with clear owners and deadlines.
8. Effectiveness verification: Establish objective evidence that the actions addressed the underlying problem.

Investigators may challenge conclusions that are unsupported by evidence, investigations with unexplained gaps, or repeated events that have not resulted in effective systemic improvement.

Practical example: If a tablet compression process repeatedly produces weight variation, retraining the operator alone may not be sufficient. The investigation should also evaluate feeder performance, powder flow, tooling condition, machine settings, process variability, and the effectiveness of established controls.

6. CAPA Effectiveness and Quality System Performance

Corrective and Preventive Action (CAPA) is an essential component of the pharmaceutical quality management system. The important question is not simply whether a CAPA has been closed, but whether the action has effectively controlled the identified problem.

Weak CAPA programs may close records without adequately addressing systemic causes, repeat deviations, or failures in process controls.

Recommended CAPA effectiveness measures

• Recurrence of the same or similar deviations.
• Reduction in repeat laboratory failures and manufacturing incidents.
• Improvement in complaint trends and product-quality indicators.
• Successful completion of defined effectiveness checks.
• Reduction in overdue CAPAs and overdue investigations.
• Evidence that procedural and process changes are sustained.
• Verification that actions have not introduced new quality risks.

Effectiveness criteria should be established before implementation and should be appropriate to the risk. Where suitable, the evaluation should use objective data over a defined monitoring period.

Management should review recurring failures and ensure that resources are available to resolve cross-functional quality problems.

7. Laboratory Controls and OOS Investigations

Laboratory controls remain a key component of pharmaceutical GMP inspections. Investigators may examine whether analytical methods are suitable, laboratory procedures are followed, original data are retained, and atypical results are scientifically investigated.

Important laboratory compliance areas

• Out-of-Specification (OOS) and Out-of-Trend (OOT) investigations.
• Original chromatographic data and audit-trail review.
• Analytical method validation or verification, as applicable.
• Reference standards, reagents, and volumetric solution controls.
• Instrument calibration, qualification, and maintenance.
• Analyst training and adherence to approved procedures.
• Sample preparation, solution stability, and sample traceability.
• Scientific justification for retesting and resampling.

An OOS investigation should not be invalidated merely because a subsequent test produces a passing result. The laboratory must establish a scientifically supported reason for invalidating the original result, where appropriate.

Laboratory investigations should also evaluate whether other batches, products, methods, instruments, or analysts could be affected.

For additional guidance, consult the FDA’s Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.

8. Manufacturing Controls and Process Validation

Manufacturing inspections evaluate whether the approved process is consistently executed and whether the company maintains appropriate control over critical process parameters and quality attributes.

For oral solid dosage manufacturing, important areas may include dispensing, granulation, drying, blending, compression, coating, and packing, depending on the facility and inspection scope.

Key areas for QA and Production

• Adherence to approved master batch manufacturing and packaging records.
• Line clearance and prevention of product or material mix-ups.
• In-process controls and documented response to process excursions.
• Process Performance Qualification (PPQ) and ongoing process verification.
• Critical Process Parameter (CPP) and Critical Quality Attribute (CQA) monitoring.
• Yield reconciliation, material reconciliation, and investigation of discrepancies.
• Equipment qualification, calibration, and preventive maintenance.
• Change control for equipment, processes, materials, and manufacturing instructions.

Continued Process Verification

Continued Process Verification (CPV) should provide evidence that a validated process remains in a state of control during routine commercial manufacturing.

Trending may include assay, dissolution, content uniformity, tablet weight, hardness, friability, yield, and relevant process parameters, depending on the product and control strategy.

QA should evaluate trends, investigate meaningful signals, and ensure that significant process changes are assessed through the appropriate quality and regulatory pathways.

9. Cleaning, Contamination Control, and Equipment Maintenance

Cleaning effectiveness, equipment condition, and contamination prevention are important elements of pharmaceutical GMP compliance. The applicable risks depend on the product, manufacturing process, facility design, and equipment used.

Areas requiring attention

• Cleaning validation and cleaning verification.
• Scientific justification of residue acceptance limits.
• Dirty and clean equipment hold-time controls.
• Equipment maintenance and condition monitoring.
• Prevention of cross-contamination and product mix-ups.
• Dust extraction and appropriate material handling.
• Calibration and qualification of critical equipment.
• Environmental and microbiological controls where applicable.

For sterile manufacturing, contamination control strategy, aseptic processing practices, environmental monitoring, personnel qualification, and investigation of microbiological excursions are particularly important.

For non-sterile oral dosage facilities, the assessment should be appropriate to risks such as shared equipment, potent compounds, dust generation, residues, and material transfer.

Companies should avoid treating equipment maintenance and cleaning as isolated technical functions. Their effectiveness should be reflected in deviation trends, process performance, and product-quality outcomes.

10. Supplier Qualification and Supply Chain Oversight

Pharmaceutical product quality depends on the controls applied to raw materials, active pharmaceutical ingredients (APIs), excipients, packaging materials, contract laboratories, and outsourced manufacturing operations.

Supplier oversight should be based on the criticality of the material or service and the associated quality risks.

Important supplier-management activities

• Initial qualification and risk-based supplier assessment.
• Verification of material specifications and supplier documentation.
• Supplier audits based on appropriate risk and oversight requirements.
• Investigation of incoming material failures and recurring discrepancies.
• Management of supplier changes through formal change control.
• Monitoring of supplier performance and quality agreements.
• Evaluation of supply-chain risks and potential product-quality impacts.

Where responsibilities are shared between a marketing authorization holder, contract manufacturer, and testing laboratory, each organization should understand its assigned quality responsibilities.

Supplier qualification should not be treated as a one-time approval. Ongoing performance monitoring and reassessment are necessary to determine whether the controls remain effective.

11. Remote Regulatory Assessments and Records Requests

The FDA continues to use a range of regulatory assessment tools to support oversight of pharmaceutical manufacturing facilities. Depending on the circumstances, these may include on-site inspections, records requests, Remote Regulatory Assessments (RRAs), remote interactive evaluations, and information from trusted regulatory partners.

In September 2025, the FDA issued final guidance describing its use of alternative tools to evaluate manufacturing facilities associated with pending drug applications. These tools may be used before, instead of, or in support of certain pre-approval or pre-license inspections, where appropriate.

The FDA also reported increased use of records-request reviews under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in fiscal year 2025 to support risk-based application decisions.

How should companies prepare for remote assessments?

• Maintain accurate and complete records in an organized format.
• Ensure the relevant subject-matter experts are available.
• Verify that electronic systems can retrieve requested records efficiently.
• Ensure electronic files are legible, complete, and traceable to original records.
• Establish an internal process for reviewing and approving regulatory responses.
• Maintain consistency between submitted records, actual operations, and approved procedures.

Remote assessment tools do not remove the obligation to comply with applicable GMP requirements. The FDA determines which tools are suitable for a particular regulatory decision or inspectional objective.

Reference: FDA Issues Final Guidance on Using Remote Oversight Tools to Help Approve Drugs.

12. Pre-Approval Inspections and Application Readiness

Pre-Approval Inspections (PAIs) and Pre-License Inspections (PLIs) assess whether a manufacturing facility is capable of producing products in accordance with applicable CGMP requirements and the information submitted in the regulatory application.

These assessments may evaluate manufacturing readiness, quality systems, process controls, data integrity, and the consistency of actual facility operations with the application.

Important PAI/PLI preparation activities

• Verify that the facility and relevant operations match the application information.
• Ensure master batch records and supporting documents are approved and controlled.
• Confirm that validation activities are complete or appropriately addressed for the inspection stage.
• Verify that analytical methods, specifications, and testing arrangements are suitable.
• Ensure manufacturing equipment and computerized systems have appropriate qualification or validation status.
• Review deviations, change controls, and CAPAs associated with the application product.
• Ensure personnel can explain the manufacturing process and associated quality controls.

The FDA published an updated Pre-Approval Inspection compliance program on June 29, 2026, and a new Pre-License Inspection compliance program on April 14, 2026, as reported in its manufacturing oversight updates.

These program documents provide insight into the FDA’s risk-based approach to evaluating facilities supporting drug applications.

Reference: FDA Actions to Support and Strengthen Domestic Drug Manufacturing.

13. Quality Management Maturity: Beyond Basic GMP Compliance

Quality Management Maturity (QMM) is an FDA initiative intended to encourage pharmaceutical manufacturers to adopt quality management practices that go beyond baseline CGMP requirements.

The objective is to encourage stronger quality culture, continuous improvement, reliable manufacturing performance, and a more resilient drug supply chain.

QMM should not be confused with a replacement for CGMP requirements or a universal certification that automatically demonstrates compliance.

How pharmaceutical companies can strengthen quality maturity

• Encourage employees to report quality concerns without inappropriate pressure.
• Use quality metrics to identify systemic problems rather than merely report completed activities.
• Strengthen management review of recurring deviations and ineffective CAPAs.
• Use process data to identify emerging risks and opportunities for improvement.
• Invest in workforce training and technical competency.
• Evaluate the effectiveness of digital quality systems and process controls.
• Promote collaboration between QA, QC, Production, Engineering, and Supply Chain teams.

A mature quality system demonstrates not only that procedures exist, but also that management and employees consistently use them to prevent failures and improve product quality.

Reference: FDA: Ensuring Quality and Access — FDA’s Approach to Generic Drug Oversight.

14. USFDA Inspection Readiness Checklist for Pharmaceutical Companies

The following checklist can be used during routine internal assessments and mock inspections. It should be adapted to the facility’s products, processes, applicable regulations, and inspection scope.

Recommended inspection-readiness routine

1. Daily: Maintain GMP compliance and accurate contemporaneous records.
2. Weekly: Review significant open deviations, critical actions, and overdue quality activities.
3. Monthly: Trend quality metrics, recurring events, complaints, and CAPA effectiveness.
4. Quarterly: Conduct focused internal assessments of high-risk processes and systems.
5. Periodically: Conduct cross-functional mock inspections, evaluate systemic gaps, and verify completion of improvement actions.

The frequency of each activity should be established according to the company’s procedures and risk-management framework. These intervals are recommendations, not universal FDA-mandated frequencies.

15. Common Inspection Findings and How to Prevent Them

The following table summarizes recurring pharmaceutical GMP risk areas. It is a practical prevention guide, not a claim that every item represents a new or increased FDA finding in 2026.

The best prevention strategy is to identify and correct weaknesses before they recur. A mock inspection is useful only when the resulting findings lead to sustainable improvements in the underlying quality system.

16. Conclusion

The latest USFDA inspection developments in 2026 reinforce the importance of continuous inspection readiness, effective quality systems, reliable data, and risk-based oversight.

The increased use of unannounced foreign inspections, continued use of alternative assessment tools, and emphasis on manufacturing quality and supply chain reliability make it important for pharmaceutical companies to maintain consistent GMP practices throughout the year.

For QA leaders, the priority should be to strengthen investigations, improve CAPA effectiveness, maintain data integrity, monitor process performance, and ensure that actual manufacturing practices remain consistent with approved procedures and regulatory commitments.

Successful inspection readiness is not achieved by preparing documents only when an inspector arrives. It is achieved by maintaining a strong quality culture, reliable records, technically sound processes, and effective management oversight every day.

Remember: Compliance should be demonstrated through the way the pharmaceutical quality system operates, not merely through the existence of documented procedures.

References and Further Reading

1. FDA — Investing in FDA’s Inspectional Enterprise
2. FDA — Actions to Support and Strengthen Domestic Drug Manufacturing
3. FDA — Risk-Based Approach to Inspections
4. FDA — Data Integrity and Compliance With Drug CGMP
5. FDA — Investigating Out-of-Specification Test Results for Pharmaceutical Production
6. FDA — Final Guidance on Using Remote Oversight Tools to Help Approve Drugs
7. FDA — Ensuring Quality and Access: Approach to Generic Drug Oversight